A Phase 3 interventional study of Placebo and Brivaracetam 2.5 mg in Epilepsy, sponsored by UCB Pharma. Completed at 70 sites in 5 countries. Open to participants aged 16 Years to 70 Years. Per ClinicalTrials.gov, last updated 2022-07-21.
Sponsored by UCB Pharma (part of UCB S.A.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies testing brivaracetam in Epilepsy — 2 open to participants now, 2 under way, 1 of them phase 3. brivaracetam · Epilepsy.
Among the 34 studies testing brivaracetam in Epilepsy, this one is the 7th largest by enrollment, is one of 3 that started in 2007, is one of 21 in phase 3, and was the 8th registered.
1,848 studies on the registry are indexed under Epilepsy; 419 are open to participants now.
Browse Epilepsy studies →2 of the 34 studies testing brivaracetam in Epilepsy are open now, in 12 countries. Recruiting first, the newest first:
UCB Biopharma SRL · Sites in United States, Belgium, Czechia and 8 more countries
Ages 1 mo+
Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. · Sites in China
Ages 18–55 · Healthy volunteers
By country, each count listing its studies:
brivaracetam: first FDA approval 2016 (BRIVIACT), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 284 Epilepsy studies recruiting now, 114 (40%) set no upper age limit and 147 (52%) stop at 75 or younger; 139 take children under 18; 55 take healthy volunteers.
This study: 16 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 3 started in 2007.
This study's enrollment of 400 is above the median of 50 across 1,239 interventional studies indexed under Epilepsy.
Median enrollment 94 across the 34 interventional studies. Of the 31 that completed or were terminated, 23 (74%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 34 have an industry lead sponsor. The 10 most frequent:
This study is registered under UCB Pharma, one of the names counted as UCB S.A.. Under that name alone:
UCB Pharma is the lead sponsor of 242 studies on the registry; none are open to participants now.
128 studies in Epilepsy by UCB S.A.: 2 open now, 2 under way, 2 of them phase 3. Of 121 finished, 90 (74%) have results posted.
Among the 128 studies in Epilepsy by UCB S.A., this one is the 19th largest by enrollment of the 116 interventional ones that give a count, is one of 9 that started in 2007, is one of 74 in phase 3, and was the 33rd registered.
UCB S.A.’s Epilepsy studies by the year they started, since 1998.
None of the studies under way reaches primary completion within a year.
Among the 34 studies testing brivaracetam in Epilepsy, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among UCB S.A.’s 128 in Epilepsy:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will evaluate the efficacy and safety of Brivaracetam to support the submission file in the indication of adjunctive treatment in adolescents and adults with partial onset seizures.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Matching Placebo tablets administered twice a day. Daily oral dose of two equal intakes, morning and evening, of Placebo in a double-blinded way for the 12-week Treatment Period.
Other: Placebo
Brivaracetam 5 mg/day, 2.5 mg administered twice a day. Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 5 mg /day in a double-blinded way for the 12-week Treatment Period.
Drug: Brivaracetam 2.5 mg
Brivaracetam 20 mg/day, 10 mg administered twice a day. Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 20 mg /day in a double-blinded way for the 12-week Treatment Period.
Drug: Brivaracetam 10 mg
Brivaracetam 50 mg/day, 25 mg administered twice a day. Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 50 mg /day, in a double-blinded way for the 12-week Treatment Period.
Drug: Brivaracetam 25 mg
* Active Substance: Placebo * Pharmaceutical Form: Film-coated tablet * Concentration: 2.5 mg, 10 mg and 25 mg * Route of Administration: Oral use
* Active Substance: Brivaracetam * Pharmaceutical Form: Film-coated tablet * Concentration: 2.5 mg * Route of Administration: Oral use
* Active Substance: Brivaracetam * Pharmaceutical Form: Film-coated tablet * Concentration: 10 mg * Route of Administration: Oral use
* Active Substance: Brivaracetam * Pharmaceutical Form: Film-coated tablet * Concentration: 25 mg * Route of Administration: Oral use
Partial Onset Seizure (Type I) Frequency Per Week Over the 12-week Treatment Period
Partial (Type I) seizures can be classified into one of the following three groups: * Simple partial seizures * Complex partial seizures * Partial seizures evolving to generalized tonic-clonic convulsions. Partial Onset Seizure (POS) Frequency per week over the Treatment Period (TP) was calculated as: (Total Type I seizures over the TP)\*7/(Total number of days with no missing seizure count in the TP)
Time frame: Baseline to 12-week Treatment Period
Responder Rate for Partial Onset Seizure (Type I) Frequency Per Week Over the 12-week Treatment Period
The responder rate was presented as the number of responders and non-responders. A subject is a responder, if the subject has at least 50 % reduction in partial onset seizure frequency per week from Baseline to Treatment Period. Subjects with zero seizure frequency per week at Baseline were considered as non-responders.
Time frame: Baseline to 12-week Treatment Period
All Seizure Frequency (Type I+II+III) Per Week Over the 12-week Treatment Period
There are three different types of seizures: * Type I: Partial seizures * Type II: Generalized seizures * Type III: Unclassified epileptic seizures. All seizure frequency per week over Treatment Period (TP) was calculated as: (Total number of seizures over the TP)\*7/(Total number of days with no missing seizure count in the TP)
Time frame: Baseline to 12-week Treatment Period
Percent Change From Baseline to the 12-week Treatment Period in Partial Onset Seizure (Type I) Frequency Per Week
Percent change from Baseline was calculated as percent reduction by: (weekly seizure frequency Baseline - weekly seizure frequency Treatment)\*100/(weekly seizure frequency Baseline). The higher the values for percent change in Partial Onset Seizure (POS) frequency, the higher the improvement from Baseline.
Time frame: Baseline to 12-week Treatment Period
Categorized Percentage Change From Baseline in Seizure Frequency for Partial Onset Seizure (Type I) Over the 12-week Treatment Period
Subjects were classified in 1 of the following categories based on their percent reduction from Baseline to Treatment Period in Partial Onset Seizure (POS) frequency per week: \<-25 %, -25 % to \<25 %, 25 % to \<50 %, 50 % to \<75 %, 75 % to \<100 %, and 100 %. Subjects having zero for Baseline seizure frequency per week were classified in the \<-25 % category.
Time frame: Baseline to 12-week Treatment Period
Seizure Freedom Rate (All Seizure Types) Over the 12-week Treatment Period
Subjects were considered seizure free if their seizure counts for every day over the Treatment Period (TP) was zero and if they did not discontinue before the end of the TP. Seizure freedom rate was calculated as: (total number of seizure - free subjects in treatment group during TP)/(total number of evaluable Intent-To-Treat (ITT) subjects in treatment group)
Time frame: Baseline to 12-week Treatment Period
Time to First Type I Seizure During the 12-week Treatment Period
The time to first Partial Onset Seizure (POS) in the Treatment Period is defined as the time between beginning of the Treatment Period and the date of occurrence of first Type I seizure. Subjects withdrawing during the Treatment Period before having a first Type I seizure were considered as having a first Type I seizure on the last day of their Treatment Period.
Time frame: Baseline to 12-week Treatment Period
Time to Fifth Type I Seizure During the 12-week Treatment Period
The time to fifth Partial Onset Seizure (POS) in the Treatment Period is defined as the time between beginning of the Treatment Period and the date of occurrence of fifth Type I seizure. Subjects withdrawing during the Treatment Period before having a fifth Type I seizure were considered as having a fifth Type I seizure on the last day of their Treatment Period.
Time frame: Baseline to 12-week Treatment Period
Time to Tenth Type I Seizure During the 12-week Treatment Period
The time to tenth Partial Onset Seizure (POS) in the Treatment Period is defined as the time between beginning of the Treatment Period and the date of occurrence of tenth Type I seizure. Subjects withdrawing during the Treatment Period before having a tenth Type I seizure were considered as having a tenth Type I seizure on the last day of their Treatment Period.
Time frame: Baseline to 12-week Treatment Period
Reduction of Type IC/Type I Seizure Frequency Ratio From Baseline to the 12- Week Treatment Period
The type IC/Type I seizure frequency ratio is represented by the percentage of subjects having a reduction in the ratio of Type IC seizure frequency over Type IA, IB, and IC seizure frequency from Baseline to Treatment Period.
Time frame: Baseline to 12-week Treatment Period
Change From Baseline to the 12-week Treatment Period in Total Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score
The Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-items subscales - seizure worry (5 items), overall quality of life (2 items), emotional well-being (5 items), energy / fatigue (4 items), cognitive functioning (6 items), medication effects (3 items), and social function (5 items) - and a health status item. The subscale scores, the total score and the health status item score range from 0 to 100 and higher scores indicating better function.
Time frame: Baseline to 12-week Treatment Period
Change From Baseline to the 12-week Treatment Period in Seizure Worry Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score
The Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-items subscales - seizure worry (5 items), overall quality of life (2 items), emotional well-being (5 items), energy / fatigue (4 items), cognitive functioning (6 items), medication effects (3 items), and social function (5 items) - and a health status item. The subscale scores, the total score and the health status item score range from 0 to 100 and higher scores indicating better function.
Time frame: Baseline to 12-week Treatment Period
Change From Baseline to the 12-week Treatment Period in Daily Activities / Social Functioning Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score
The Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-items subscales - seizure worry (5 items), overall quality of life (2 items), emotional well-being (5 items), energy / fatigue (4 items), cognitive functioning (6 items), medication effects (3 items), and social function (5 items) - and a health status item. The subscale scores, the total score and the health status item score range from 0 to 100 and higher scores indicating better function.
Time frame: Baseline to 12-week Treatment Period
Change From Baseline to the 12-week Treatment Period in Hospital Anxiety Score
The Hospital Anxiety and Depression Scale (HADS) was used to evaluate anxiety and depression. The HADS was developed as a self administered scale to assess the presence and severity of both anxiety and depression simultaneously. It consists of 14 items that are scored on a 4-point severity scale ranging from 0 to 3. A score per dimension was calculated with each score ranging from 0 to 21 and higher scores indicating higher depression / anxiety. A negative value in change from Baseline shows an improvement in HADS from Baseline.
Time frame: Baseline to 12-week Treatment Period
Change From Baseline to the 12-week Treatment Period in Hospital Depression Score
The Hospital Anxiety and Depression Scale (HADS) was used to evaluate anxiety and depression. The HADS was developed as a self administered scale to assess the presence and severity of both anxiety and depression simultaneously. It consists of 14 items that are scored on a 4-point severity scale ranging from 0 to 3. A score per dimension was calculated with each score ranging from 0 to 21 and higher scores indicating higher depression / anxiety. A negative value in change from Baseline shows an improvement in HADS from Baseline.
Time frame: Baseline to 12-week Treatment Period
Patient's Global Evaluation Scale (P-GES) Evaluated at Last Visit or Early Discontinuation Visit
Patient's Global Evaluation Scale (P-GES) is a global assessment of the disease evolution which was performed using a seven-point scale (1= Marked worsening to 7 = Marked improvement) with the start of the study medication as the reference time point. The subject completed it by answering to the following: 'Overall, has there been a change in your seizures since the start of the study medication?'
Time frame: Baseline to Last Visit or Early Discontinuation Visit in the 12-week Treatment Period
Investigator's Global Evaluation Scale (I-GES) Evaluated at Last Visit or Early Discontinuation Visit
The Investigator's Global Evaluation Scale (I-GES) is a global assessment of the disease evolution which was performed using a seven-point scale (1 = Marked worsening to 7 = Marked improvement) with the start of the study medication as the reference time point. The investigator completed it by answering to the following: 'Assess the overall change in the severity of patient's illness, compared to start of study medication.'
Time frame: Baseline to Last Visit or Early Discontinuation Visit in the 12-week Treatment Period
Change From Baseline to the 12-week Treatment Period in Energy/Fatigue Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score
The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline.
Time frame: From Baseline to 12-week Treatment Period
Change From Baseline to the 12-week Treatment Period in Emotional Well-Being Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score
The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline.
Time frame: From Baseline to 12-week Treatment Period
Change From Baseline to the 12-week Treatment Period in Cognitive Functioning Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score
The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline.
Time frame: From Baseline to 12-week Treatment Period
Change From Baseline to the 12-week Treatment Period in Medication Effects Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score
The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline.
Time frame: From Baseline to 12-week Treatment Period
Change From Baseline to the 12-week Treatment Period in Overall Quality of Life Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score
The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline.
Time frame: From Baseline to 12-week Treatment Period
Change From Baseline to the 12-week Treatment Period in Health Status of Life Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score
The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline.
Time frame: From Baseline to 12-week Treatment Period
This study started to enroll subjects in September 2007 and concluded in January 2009. 400 subjects were randomized of which 396 are included in the Safety Population.
| Milestone | Placebo | BRV 5 mg/Day | BRV 20 mg/Day | BRV 50 mg/Day |
|---|---|---|---|---|
| Started | 99 | 99 | 100 | 102 |
| Completed | 93 | 82 | 93 | 93 |
| Not completed | 6 | 17 | 7 | 9 |
| Withdrew: Lack of efficacy | 1 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 4 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 2 | 1 | 1 |
| Withdrew: Other reason | 3 | 3 | 1 | 1 |
| Withdrew: Ae, serious fatal | 0 | 0 | 1 | 1 |
| Withdrew: Sae, non-fatal | 0 | 0 | 0 | 1 |
| Withdrew: Ae, non-serious non-fatal | 2 | 8 | 3 | 4 |
| Withdrew: Sae,non-fatal+ae,non-serious non-fatal | 0 | 0 | 1 | 0 |
Partial (Type I) seizures can be classified into one of the following three groups: * Simple partial seizures * Complex partial seizures * Partial seizures evolving to generalized tonic-clonic convulsions. Partial Onset Seizure (POS) Frequency per week over the Treatment Period (TP) was calculated as: (Total Type I seizures over the TP)\*7/(Total number of days with no missing seizure count in the TP)
| seizures per week | Modified Intention-to-Treat (Placebo Treated Subjects) | Modified Intention-to-Treat (BRV 5 mg/Day Treated Subjects) | Modified Intention-to-Treat (BRV 20 mg/Day Treated Subjects) | Modified Intention-to-Treat (BRV 50 mg/Day Treated Subjects) |
|---|---|---|---|---|
| Partial Onset Seizure (Type I) Frequency Per Week Over the 12-week Treatment Period | 2.15 (1.43 to 4.15) | 1.80 (0.99 to 5.59) | 1.96 (1.05 to 5.45) | 1.70 (0.91 to 4.80) |
The responder rate was presented as the number of responders and non-responders. A subject is a responder, if the subject has at least 50 % reduction in partial onset seizure frequency per week from Baseline to Treatment Period. Subjects with zero seizure frequency per week at Baseline were considered as non-responders.
| participants | Modified Intention-to-Treat (Placebo Treated Subjects) | Modified Intention-to-Treat (BRV 5 mg/Day Treated Subjects) | Modified Intention-to-Treat (BRV 20 mg/Day Treated Subjects) | Modified Intention-to-Treat (BRV 50 mg/Day Treated Subjects) |
|---|---|---|---|---|
| Responders | 16 | 21 | 23 | 33 |
| Non-responders | 80 | 75 | 76 | 68 |
There are three different types of seizures: * Type I: Partial seizures * Type II: Generalized seizures * Type III: Unclassified epileptic seizures. All seizure frequency per week over Treatment Period (TP) was calculated as: (Total number of seizures over the TP)\*7/(Total number of days with no missing seizure count in the TP)
| seizures per week | Modified Intention-to-Treat (Placebo Treated Subjects) | Modified Intention-to-Treat (BRV 5 mg/Day Treated Subjects) | Modified Intention-to-Treat (BRV 20 mg/Day Treated Subjects) | Modified Intention-to-Treat (BRV 50 mg/Day Treated Subjects) |
|---|---|---|---|---|
| All Seizure Frequency (Type I+II+III) Per Week Over the 12-week Treatment Period | 2.15 (1.45 to 4.23) | 1.80 (0.99 to 5.59) | 1.96 (1.05 to 5.85) | 1.77 (0.99 to 4.80) |
Percent change from Baseline was calculated as percent reduction by: (weekly seizure frequency Baseline - weekly seizure frequency Treatment)\*100/(weekly seizure frequency Baseline). The higher the values for percent change in Partial Onset Seizure (POS) frequency, the higher the improvement from Baseline.
| Percent change in POS frequency | Modified Intention-to-Treat (Placebo Treated Subjects) | Modified Intention-to-Treat (BRV 5 mg/Day Treated Subjects) | Modified Intention-to-Treat (BRV 20 mg/Day Treated Subjects) | Modified Intention-to-Treat (BRV 50 mg/Day Treated Subjects) |
|---|---|---|---|---|
| Percent Change From Baseline to the 12-week Treatment Period in Partial Onset Seizure (Type I) Frequency Per Week | 17.75 (-5.11 to 37.07) | 19.95 (-12.96 to 45.15) | 22.52 (-4.56 to 46.51) | 30.47 (11.40 to 59.78) |
Subjects were classified in 1 of the following categories based on their percent reduction from Baseline to Treatment Period in Partial Onset Seizure (POS) frequency per week: \<-25 %, -25 % to \<25 %, 25 % to \<50 %, 50 % to \<75 %, 75 % to \<100 %, and 100 %. Subjects having zero for Baseline seizure frequency per week were classified in the \<-25 % category.
| percentage of participants | Modified Intention-to-Treat (Placebo Treated Subjects) | Modified Intention-to-Treat (BRV 5 mg/Day Treated Subjects) | Modified Intention-to-Treat (BRV 20 mg/Day Treated Subjects) | Modified Intention-to-Treat (BRV 50 mg/Day Treated Subjects) |
|---|---|---|---|---|
| <-25 % | 14.6 | 21.9 | 14.1 | 9.9 |
| -25 % to < 25 % | 44.8 | 31.3 | 38.4 | 31.7 |
| 25 % to < 50 % | 24.0 | 25.0 | 24.2 | 25.7 |
| 50 % to < 75 % | 12.5 | 12.5 | 15.2 | 19.8 |
| 75 % to < 100 % | 4.2 | 8.3 | 6.1 | 8.9 |
| 100 % | 0 | 1.0 | 2.0 | 4.0 |
Subjects were considered seizure free if their seizure counts for every day over the Treatment Period (TP) was zero and if they did not discontinue before the end of the TP. Seizure freedom rate was calculated as: (total number of seizure - free subjects in treatment group during TP)/(total number of evaluable Intent-To-Treat (ITT) subjects in treatment group)
| percentage of participants | Modified Intention-to-Treat (Placebo Treated Subjects) | Modified Intention-to-Treat (BRV 5 mg/Day Treated Subjects) | Modified Intention-to-Treat (BRV 20 mg/Day Treated Subjects) | Modified Intention-to-Treat (BRV 50 mg/Day Treated Subjects) |
|---|---|---|---|---|
| Seizure-free | 0 | 1.0 | 1.0 | 4.0 |
| No seizures but non-completer | 0 | 0 | 1.0 | 0 |
| Not seizure-free | 100.0 | 99.0 | 98.0 | 96.0 |
The time to first Partial Onset Seizure (POS) in the Treatment Period is defined as the time between beginning of the Treatment Period and the date of occurrence of first Type I seizure. Subjects withdrawing during the Treatment Period before having a first Type I seizure were considered as having a first Type I seizure on the last day of their Treatment Period.
| days | Modified Intention-to-Treat (Placebo Treated Subjects) | Modified Intention-to-Treat (BRV 5 mg/Day Treated Subjects) | Modified Intention-to-Treat (BRV 20 mg/Day Treated Subjects) | Modified Intention-to-Treat (BRV 50 mg/Day Treated Subjects) |
|---|---|---|---|---|
| Time to First Type I Seizure During the 12-week Treatment Period | 3 (2 to 3) | 4 (2 to 5) | 5 (3 to 7) | 4 (3 to 6) |
The time to fifth Partial Onset Seizure (POS) in the Treatment Period is defined as the time between beginning of the Treatment Period and the date of occurrence of fifth Type I seizure. Subjects withdrawing during the Treatment Period before having a fifth Type I seizure were considered as having a fifth Type I seizure on the last day of their Treatment Period.
| days | Modified Intention-to-Treat (Placebo Treated Subjects) | Modified Intention-to-Treat (BRV 5 mg/Day Treated Subjects) | Modified Intention-to-Treat (BRV 20 mg/Day Treated Subjects) | Modified Intention-to-Treat (BRV 50 mg/Day Treated Subjects) |
|---|---|---|---|---|
| Time to Fifth Type I Seizure During the 12-week Treatment Period | 15 (12 to 16) | 14 (12 to 18) | 17 (14 to 21) | 19 (16 to 25) |
The time to tenth Partial Onset Seizure (POS) in the Treatment Period is defined as the time between beginning of the Treatment Period and the date of occurrence of tenth Type I seizure. Subjects withdrawing during the Treatment Period before having a tenth Type I seizure were considered as having a tenth Type I seizure on the last day of their Treatment Period.
| days | Modified Intention-to-Treat (Placebo Treated Subjects) | Modified Intention-to-Treat (BRV 5 mg/Day Treated Subjects) | Modified Intention-to-Treat (BRV 20 mg/Day Treated Subjects) | Modified Intention-to-Treat (BRV 50 mg/Day Treated Subjects) |
|---|---|---|---|---|
| Time to Tenth Type I Seizure During the 12-week Treatment Period | 28 (24 to 33) | 30 (21 to 38) | 34 (25 to 46) | 37 (27 to 52) |
The type IC/Type I seizure frequency ratio is represented by the percentage of subjects having a reduction in the ratio of Type IC seizure frequency over Type IA, IB, and IC seizure frequency from Baseline to Treatment Period.
| percentage of participants | Modified Intention-to-Treat (Placebo Treated Subjects) | Modified Intention-to-Treat (BRV 5 mg/Day Treated Subjects) | Modified Intention-to-Treat (BRV 20 mg/Day Treated Subjects) | Modified Intention-to-Treat (BRV 50 mg/Day Treated Subjects) |
|---|---|---|---|---|
| Reduction of Type IC/Type I Seizure Frequency Ratio From Baseline to the 12- Week Treatment Period | 56.3 | 50.0 | 77.8 | 63.6 |
The Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-items subscales - seizure worry (5 items), overall quality of life (2 items), emotional well-being (5 items), energy / fatigue (4 items), cognitive functioning (6 items), medication effects (3 items), and social function (5 items) - and a health status item. The subscale scores, the total score and the health status item score range from 0 to 100 and higher scores indicating better function.
| units on a scale | Modified Intention-to-Treat (Placebo Treated Subjects) | Modified Intention-to-Treat (BRV 5 mg/Day Treated Subjects) | Modified Intention-to-Treat (BRV 20 mg/Day Treated Subjects) | Modified Intention-to-Treat (BRV 50 mg/Day Treated Subjects) |
|---|---|---|---|---|
| Change From Baseline to the 12-week Treatment Period in Total Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score | 3.88 ± 14.44 | 4.07 ± 15.40 | 5.19 ± 15.47 | 2.88 ± 13.53 |
The Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-items subscales - seizure worry (5 items), overall quality of life (2 items), emotional well-being (5 items), energy / fatigue (4 items), cognitive functioning (6 items), medication effects (3 items), and social function (5 items) - and a health status item. The subscale scores, the total score and the health status item score range from 0 to 100 and higher scores indicating better function.
| units on a scale | Modified Intention-to-Treat (Placebo Treated Subjects) | Modified Intention-to-Treat (BRV 5 mg/Day Treated Subjects) | Modified Intention-to-Treat (BRV 20 mg/Day Treated Subjects) | Modified Intention-to-Treat (BRV 50 mg/Day Treated Subjects) |
|---|---|---|---|---|
| Change From Baseline to the 12-week Treatment Period in Seizure Worry Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score | 9.36 ± 26.98 | 3.34 ± 19.20 | 3.69 ± 24.55 | 5.97 ± 21.79 |
The Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-items subscales - seizure worry (5 items), overall quality of life (2 items), emotional well-being (5 items), energy / fatigue (4 items), cognitive functioning (6 items), medication effects (3 items), and social function (5 items) - and a health status item. The subscale scores, the total score and the health status item score range from 0 to 100 and higher scores indicating better function.
| units on a scale | Modified Intention-to-Treat (Placebo Treated Subjects) | Modified Intention-to-Treat (BRV 5 mg/Day Treated Subjects) | Modified Intention-to-Treat (BRV 20 mg/Day Treated Subjects) | Modified Intention-to-Treat (BRV 50 mg/Day Treated Subjects) |
|---|---|---|---|---|
| Change From Baseline to the 12-week Treatment Period in Daily Activities / Social Functioning Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score | 1.97 ± 28.39 | 7.03 ± 23.47 | 7.73 ± 26.04 | 2.06 ± 23.02 |
The Hospital Anxiety and Depression Scale (HADS) was used to evaluate anxiety and depression. The HADS was developed as a self administered scale to assess the presence and severity of both anxiety and depression simultaneously. It consists of 14 items that are scored on a 4-point severity scale ranging from 0 to 3. A score per dimension was calculated with each score ranging from 0 to 21 and higher scores indicating higher depression / anxiety. A negative value in change from Baseline shows an improvement in HADS from Baseline.
| units on a scale | Modified Intention-to-Treat (Placebo Treated Subjects) | Modified Intention-to-Treat (BRV 5 mg/Day Treated Subjects) | Modified Intention-to-Treat (BRV 20 mg/Day Treated Subjects) | Modified Intention-to-Treat (BRV 50 mg/Day Treated Subjects) |
|---|---|---|---|---|
| Change From Baseline to the 12-week Treatment Period in Hospital Anxiety Score | 7.44 ± 4.32 | 7.32 ± 4.03 | 6.55 ± 3.94 | 7.99 ± 3.63 |
The Hospital Anxiety and Depression Scale (HADS) was used to evaluate anxiety and depression. The HADS was developed as a self administered scale to assess the presence and severity of both anxiety and depression simultaneously. It consists of 14 items that are scored on a 4-point severity scale ranging from 0 to 3. A score per dimension was calculated with each score ranging from 0 to 21 and higher scores indicating higher depression / anxiety. A negative value in change from Baseline shows an improvement in HADS from Baseline.
| units on a scale | Modified Intention-to-Treat (Placebo Treated Subjects) | Modified Intention-to-Treat (BRV 5 mg/Day Treated Subjects) | Modified Intention-to-Treat (BRV 20 mg/Day Treated Subjects) | Modified Intention-to-Treat (BRV 50 mg/Day Treated Subjects) |
|---|---|---|---|---|
| Change From Baseline to the 12-week Treatment Period in Hospital Depression Score | 5.36 ± 3.78 | 4.97 ± 4.00 | 4.82 ± 3.56 | 5.81 ± 3.70 |
Patient's Global Evaluation Scale (P-GES) is a global assessment of the disease evolution which was performed using a seven-point scale (1= Marked worsening to 7 = Marked improvement) with the start of the study medication as the reference time point. The subject completed it by answering to the following: 'Overall, has there been a change in your seizures since the start of the study medication?'
| percentage of participants | Modified Intention-to-Treat (Placebo Treated Subjects) | Modified Intention-to-Treat (BRV 5 mg/Day Treated Subjects) | Modified Intention-to-Treat (BRV 20 mg/Day Treated Subjects) | Modified Intention-to-Treat (BRV 50 mg/Day Treated Subjects) |
|---|---|---|---|---|
| Marked improvement | 15.5 | 19.8 | 18.8 | 26.7 |
| Moderate improvement | 25.0 | 24.7 | 26.3 | 19.8 |
| Slight improvement | 23.8 | 18.5 | 21.3 | 22.1 |
| No change | 28.6 | 23.5 | 27.5 | 23.3 |
| Slight worsening | 4.8 | 6.2 | 1.3 | 4.7 |
| Moderate worsening | 1.2 | 7.4 | 3.8 | 1.2 |
| Marked worsening | 1.2 | 0 | 1.3 | 2.3 |
The Investigator's Global Evaluation Scale (I-GES) is a global assessment of the disease evolution which was performed using a seven-point scale (1 = Marked worsening to 7 = Marked improvement) with the start of the study medication as the reference time point. The investigator completed it by answering to the following: 'Assess the overall change in the severity of patient's illness, compared to start of study medication.'
| percentage of participants | Modified Intention-to-Treat (Placebo Treated Subjects) | Modified Intention-to-Treat (BRV 5 mg/Day Treated Subjects) | Modified Intention-to-Treat (BRV 20 mg/Day Treated Subjects) | Modified Intention-to-Treat (BRV 50 mg/Day Treated Subjects) |
|---|---|---|---|---|
| Marked improvement | 12.6 | 12.2 | 17.2 | 16.3 |
| Moderate improvement | 20.0 | 18.9 | 18.2 | 27.6 |
| Slight improvement | 21.1 | 24.4 | 31.3 | 24.5 |
| No change | 41.1 | 34.4 | 32.3 | 25.5 |
| Slight worsening | 3.2 | 2.2 | 1.0 | 2.0 |
| Moderate worsening | 1.1 | 7.8 | 0 | 3.1 |
| Marked worsening | 1.1 | 0 | 0 | 1.0 |
The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline.
| units on a scale | Modified Intention-to-Treat (Placebo Treated Subjects) | Modified Intention-to-Treat (BRV 5 mg/Day Treated Subjects) | Modified Intention-to-Treat (BRV 20 mg/Day Treated Subjects) | Modified Intention-to-Treat (BRV 50 mg/Day Treated Subjects) |
|---|---|---|---|---|
| Change From Baseline to the 12-week Treatment Period in Energy/Fatigue Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score | 6.41 ± 19.55 | 2.24 ± 23.10 | 3.94 ± 15.56 | 0.45 ± 20.07 |
The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline.
| units on a scale | Modified Intention-to-Treat (Placebo Treated Subjects) | Modified Intention-to-Treat (BRV 5 mg/Day Treated Subjects) | Modified Intention-to-Treat (BRV 20 mg/Day Treated Subjects) | Modified Intention-to-Treat (BRV 50 mg/Day Treated Subjects) |
|---|---|---|---|---|
| Change From Baseline to the 12-week Treatment Period in Emotional Well-Being Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score | 2.14 ± 18.28 | 1.69 ± 21.61 | 2.07 ± 19.10 | 1.97 ± 17.29 |
The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline.
| units on a scale | Modified Intention-to-Treat (Placebo Treated Subjects) | Modified Intention-to-Treat (BRV 5 mg/Day Treated Subjects) | Modified Intention-to-Treat (BRV 20 mg/Day Treated Subjects) | Modified Intention-to-Treat (BRV 50 mg/Day Treated Subjects) |
|---|---|---|---|---|
| Change From Baseline to the 12-week Treatment Period in Cognitive Functioning Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score | 2.79 ± 20.34 | 4.26 ± 21.23 | 6.36 ± 24.61 | 3.37 ± 19.16 |
The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline.
| units on a scale | Modified Intention-to-Treat (Placebo Treated Subjects) | Modified Intention-to-Treat (BRV 5 mg/Day Treated Subjects) | Modified Intention-to-Treat (BRV 20 mg/Day Treated Subjects) | Modified Intention-to-Treat (BRV 50 mg/Day Treated Subjects) |
|---|---|---|---|---|
| Change From Baseline to the 12-week Treatment Period in Medication Effects Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score | 1.02 ± 34.05 | -2.61 ± 28.08 | 0.73 ± 25.94 | 6.07 ± 30.90 |
The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline.
| units on a scale | Modified Intention-to-Treat (Placebo Treated Subjects) | Modified Intention-to-Treat (BRV 5 mg/Day Treated Subjects) | Modified Intention-to-Treat (BRV 20 mg/Day Treated Subjects) | Modified Intention-to-Treat (BRV 50 mg/Day Treated Subjects) |
|---|---|---|---|---|
| Change From Baseline to the 12-week Treatment Period in Overall Quality of Life Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score | 5.49 ± 16.25 | 3.39 ± 19.70 | 3.66 ± 20.10 | 2.33 ± 19.14 |
The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline.
| units on a scale | Modified Intention-to-Treat (Placebo Treated Subjects) | Modified Intention-to-Treat (BRV 5 mg/Day Treated Subjects) | Modified Intention-to-Treat (BRV 20 mg/Day Treated Subjects) | Modified Intention-to-Treat (BRV 50 mg/Day Treated Subjects) |
|---|---|---|---|---|
| Change From Baseline to the 12-week Treatment Period in Health Status of Life Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score | 8.1 ± 22.0 | 6.9 ± 23.5 | 7.3 ± 21.1 | 5.5 ± 20.9 |
Collected over Adverse Events (AEs) were collected up to 23 weeks from Visit 1 (Week -8) to the Safety Visit (Week 15).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 0/98 (0%) | 32/98 (32.7%) |
| BRV 5 mg/Day | — | 1/97 (1%) | 49/97 (50.5%) |
| BRV 20 mg/Day | — | 3/100 (3%) | 46/100 (46%) |
| BRV 50 mg/Day | — | 4/101 (4%) | 51/101 (50.5%) |
| Event | Placebo | BRV 5 mg/Day | BRV 20 mg/Day | BRV 50 mg/Day |
|---|---|---|---|---|
| PneumoniaInfections and infestations | 0/98 | 1/97 | 0/100 | 0/101 |
| SyncopeNervous system disorders | 0/98 | 0/97 | 1/100 | 0/101 |
| Aspiration bronchialRespiratory, thoracic and mediastinal disorders | 0/98 | 0/97 | 1/100 | 0/101 |
| BronchospasmRespiratory, thoracic and mediastinal disorders | 0/98 | 0/97 | 1/100 | 0/101 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 0/98 | 0/97 | 1/100 | 0/101 |
| Abdominal painGastrointestinal disorders | 0/98 | 0/97 | 0/100 | 1/101 |
| VomitingGastrointestinal disorders | 0/98 | 0/97 | 0/100 | 1/101 |
| Chest painGeneral disorders | 0/98 | 0/97 | 0/100 | 1/101 |
| PainGeneral disorders | 0/98 | 0/97 | 0/100 | 1/101 |
| BronchitisInfections and infestations | 0/98 | 0/97 | 0/100 | 1/101 |
| Event | Placebo | BRV 5 mg/Day | BRV 20 mg/Day | BRV 50 mg/Day |
|---|---|---|---|---|
| SomnolenceNervous system disorders | 7/98 | 14/97 | 14/100 | 17/101 |
| DizzinessNervous system disorders | 9/98 | 12/97 | 14/100 | 16/101 |
| HeadacheNervous system disorders | 14/98 | 11/97 | 6/100 | 13/101 |
| FatigueGeneral disorders | 2/98 | 3/97 | 13/100 | 10/101 |
| InfluenzaInfections and infestations | 1/98 | 9/97 | 6/100 | 4/101 |
| NauseaGastrointestinal disorders | 3/98 | 4/97 | 7/100 | 6/101 |
| InsomniaPsychiatric disorders | 2/98 | 2/97 | 3/100 | 7/101 |
| Urinary tract infectionInfections and infestations | 2/98 | 3/97 | 6/100 | 1/101 |
| DiarrhoeaGastrointestinal disorders | 2/98 | 4/97 | 4/100 | 6/101 |
| Upper respiratory tract infectionInfections and infestations | 4/98 | 5/97 | 5/100 | 0/101 |
Baseline Characteristics refer to Randomized Set.
| Age, Continuous(years) | Placebo | BRV 5 mg/Day | BRV 20 mg/Day | BRV 50 mg/Day | Total Title |
|---|---|---|---|---|---|
| Mean | 37.6 ± 12.6 | 38.8 ± 11.6 | 37.3 ± 13.3 | 39.0 ± 12.3 | 38.2 ± 12.5 |
| Age, Customized(participants) | Placebo | BRV 5 mg/Day | BRV 20 mg/Day | BRV 50 mg/Day | Total Title |
|---|---|---|---|---|---|
| < 18 years | 7 | 0 | 5 | 2 | 14 |
| 18 - < 65 years | 91 | 97 | 93 | 99 | 380 |
| 65 - < 85 years | 1 | 2 | 2 | 1 | 6 |
| Sex: Female, Male(Participants) | Placebo | BRV 5 mg/Day | BRV 20 mg/Day | BRV 50 mg/Day | Total Title |
|---|---|---|---|---|---|
| Female | 55 | 49 | 48 | 50 | 202 |
| Male | 44 | 50 | 52 | 52 | 198 |
The record gives a start of Sep 2007, a primary completion of Dec 2008 and a completion of Jan 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2016, 7 years 4 months after primary completion. A results delay was requested in Feb 2010.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Brivaracetam